Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Flu Vaccines
New flu vaccines research from K.M. Zangwill et al outlined
April 2nd, 2008
"Previously, we evaluated 2 doses of H5N1 influenza vaccine in persons 18-64 years of age (placebo and 7.5-, 15-, 45-, or 90-mu g doses), separated by 28 days. In this study, 337 participants received a third dose, 6 months thereafter," scientists writing in the Journal of Infectious Diseases report. "Microneutralization (MN) and hemagglutination-inhibition geometric mean titers(GMTs) of antibody declined before the third dose. Twenty-eight days after the third dose, 78%, 67%, 43%, and 31% of recipients in the 90-, 45-, 15-, and 7.5-mu g-dose groups had a MN GMT >= 1:40, respectively," wrote K.M. Zangwill and colleagues. The researchers...
Source: Vaccine Weekly (2008-04-02)
|
